Product Code: SR112023A3906
Abstract
The global radiopharmaceuticals market size reached US$ 5.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2022-2028.
Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient's body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones.
Radiopharmaceuticals Market Trends:
The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market. Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales. Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth. Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiopharmaceuticals market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, application and end use.
Breakup by Product Type:
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
Breakup by Application:
Oncology
Cardiology
Neurology
Endocrinology
Others
Breakup by End Use:
Hospitals and Clinics
Research Institutes
Diagnostic Centers
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.
Key Questions Answered in This Report
- 1. What was the size of the global radiopharmaceuticals market in 2022?
- 2. What is the expected growth rate of the global radiopharmaceuticals market during 2023-2028?
- 3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
- 4. What are the key factors driving the global radiopharmaceuticals market?
- 5. What is the breakup of the global radiopharmaceuticals market based on the product type?
- 6. What is the breakup of the global radiopharmaceuticals market based on the application?
- 7. What is the breakup of the global radiopharmaceuticals market based on the end use?
- 8. What are the key regions in the global radiopharmaceuticals market?
- 9. Who are the key players/companies in the global radiopharmaceuticals market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Radiopharmaceuticals Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Diagnostic Nuclear Medicine
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Therapeutic Nuclear Medicine
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Application
- 7.1 Oncology
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Cardiology
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Neurology
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Endocrinology
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Research Institutes
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Diagnostic Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Advanced Accelerator Applications (Novartis AG)
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Bayer AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bracco S.p.A.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 SWOT Analysis
- 14.3.4 Cardinal Health Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Curium Pharma
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 General Electric Company
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 IBA RadioPharma Solutions
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Jubilant Pharma Limited
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Lantheus Medical Imaging Inc
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Nordion Inc. (Sotera Health)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 SWOT Analysis
- 14.3.11 NTP Radioisotopes SOC Ltd
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.12 PharmaLogic Holdings Corp.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.13 Siemens AG
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis